During the past decade, Mission Cancer and Blood - Laurel conducted 95 clinical trials. In the 10-year time frame, 95 clinical trials started and 37 clinical trials were completed, i.e. on average, 38.9% percent of trials that started reached the finish line to date. In the past 5 years, 50 clinical trials started and 22 clinical trials were completed. i.e. 44% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Mission Cancer and Blood - Laurel" #1 sponsor was "National Cancer Institute (NCI)" with 113 trials, followed by "Alliance for Clinical Trials in Oncology" with 9 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 5 trials sponsored, "NRG Oncology" with 3 trials sponsored and "SWOG Cancer Research Network" with 3 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Mission Cancer and Blood - Laurel" #1 collaborator was "NRG Oncology" with 25 trials as a collaborator, "National Cancer Institute (NCI)" with 21 trials as a collaborator, "NCIC Clinical Trials Group" with 4 trials as a collaborator, "Canadian Cancer Trials Group" with 3 trials as a collaborator and "Cancer and Leukemia Group B" with 3 trials as a collaborator. Other collaborators include 11 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Mission Cancer and Blood - Laurel" are "Recurrent Ovarian Carcinoma" (8 trials), "Stage IIIB Lung Cancer AJCC v8" (7 trials), "Ovarian Seromucinous Carcinoma" (6 trials), "Recurrent Fallopian Tube Carcinoma" (6 trials) and "Stage IV Lung Cancer AJCC v8" (6 trials). Many other conditions were trialed in "Mission Cancer and Blood - Laurel" in a lesser frequency.

Most popular intervention types in "Mission Cancer and Blood - Laurel" are "Drug" (114 trials), "Other" (81 trials), "Biological" (80 trials), "Procedure" (54 trials) and "Radiation" (27 trials). Other intervention types were less common.

The name of intervention was led by "Quality-of-Life Assessment" (43 trials), "Computed Tomography" (40 trials), "Laboratory Biomarker Analysis" (39 trials), "Biospecimen Collection" (33 trials) and "Nivolumab" (27 trials). Other intervention names were less common.

The vast majority of trials in "Mission Cancer and Blood - Laurel" are 111 trials for "All" genders, 20 trials for "Female" genders and 4 trials for "Male" genders.

Currently, there are NaN active trials in "Mission Cancer and Blood - Laurel". undefined are not yet recruiting, 45 are recruiting, 75 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Mission Cancer and Blood - Laurel, 3 suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Mission Cancer and Blood - Laurel, 6 "Phase 1" clinical trials were conducted, 71 "Phase 2" clinical trials and 75 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".